Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
179 Leser
Artikel bewerten:
(0)

Global Veterinary Anti-infectives Market, 2017-2025 - Growing Concerns About Animal Meat Quality

DUBLIN, October 13, 2017 /PRNewswire/ --

The "Global Veterinary Anti-infectives Market Analysis & Trends - Industry Forecast to 2025" report has been added to Research and Markets' offering.

Research and Markets Logo

The Global Veterinary Anti-infectives Market is poised to grow at a CAGR of around 8.9% over the next decade to reach approximately $10.4 billion by 2025

Some of the prominent trends that the market is witnessing include increasing infectious disease in animals, growing concerns about animal meat quality, and rising health awareness of pet animal.

Based on drug class the market is categorized into antifungal agents, antiparasitic agents, antiviral agents, antimicrobial agents, and other drug class. Further, antimicrobial agents separated into cephalosporins, macrolides, penicillin's, quinolones, tetracyclines, and others.

By disease the market is segmented by florfenicol, beta-lactams, aminosidine, oxytetracycline, marbofloxacin, and freeze-dried ceftiofur.

Depending on the species the market is classified into farm animal, companion animals. Further, farm animal segmented by cattle, fish, swine, sheep, and poultry. Companion animals diversified into cats, dogs, and horses.

On basis of mode of administration the market is segmented by topical, parenteral, and oral. Based on distribution channel the market is categorized into veterinary clinics, pharmacies, veterinary hospitals, and other distribution channels.

This industry report analyzes the market estimates and forecasts of all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2014, 2015 revenue estimations are presented for 2016 and forecasts from 2017 till 2025.

The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies for the existing players, new entrants and the future investors.

Key Topics Covered:

1 Market Outline
1.1 Research Methodology
1.1.1 Research Approach & Sources
1.2 Market Trends
1.3 Regulatory Factors
1.4 Product Analysis
1.5 Strategic Benchmarking
1.6 Opportunity Analysis

2 Executive Summary

3 Market Overview
3.1 Current Trends
3.1.1 Increasing infectious disease in animals
3.1.2 Growing concerns about animal meat quality
3.1.3 Rising health awareness of pet animal
3.1.4 Growth Opportunities/Investment Opportunities
3.2 Drivers
3.3 Constraints
3.4 Industry Attractiveness

4 Veterinary Anti-infectives Market, By Drug Class
4.1 Antifungal Agents
4.2 Antiparasitic Agents
4.3 Antiviral Agents
4.4 Antimicrobial Agents
4.4.1.1 Cephalosporins
4.4.1.2 Macrolides
4.4.1.3 Penicillins
4.4.1.4 Quinolones
4.4.1.5 Tetracyclines
4.4.1.6 Others
4.5 Other Drug Class

5 Veterinary Anti-infectives Market, By Disease
5.1 Florfenicol
5.2 Beta-lactams
5.3 Aminosidine
5.4 Oxytetracycline
5.5 Marbofloxacin
5.6 Freeze-dried ceftiofur

6 Veterinary Anti-Infectives Market, By Species
6.1 Farm animal
6.1.1.1 Cattle
6.1.1.2 Fish
6.1.1.3 Swine
6.1.1.4 Sheep
6.1.1.5 Poultry
6.2 Companion Animals
6.2.1.1 Cats
6.2.1.2 Dogs
6.2.1.3 Horses

7 Veterinary Anti-infectives Market, By Mode of Administration
7.1 Topical
7.2 Parenteral
7.3 Oral

8 Veterinary Anti-infectives Market, By Distribution Channel
8.1 Veterinary Clinics
8.2 Pharmacies
8.3 Veterinary Hospitals
8.4 Other Distribution Channels

9 Veterinary Anti-infectives Market, By Geography

10 Key Player Activities
10.1 Mergers & Acquisitions
10.2 Partnerships, Joint Venture's, Collaborations and Agreements
10.3 Product Launch & Expansions
10.4 Other Activities

11 Leading Companies

  • Bayer AG
  • Cipla Limited
  • Dechra Pharmaceuticals PLC
  • Eli Lilly and Company (Elanco Animal Health)
  • Heska Corp (Diamond Animal Health)
  • Merck & Co., Inc. (Merck Animal Health)
  • Neogen Corporation
  • Phibro Animal Health Corporation
  • Sanofi (Merial Animal Health)
  • Vetoquinol S.A.
  • Virbac S.A.
  • Zoetis, Inc.
  • Boehringer Ingelheim GmbH
  • Indian Immunologicals Limited
  • Intas Pharmaceuticals Limited
  • Norbrook Laboratories Limited
  • Zydus Animal Health Limited

For more information about this report visit https://www.researchandmarkets.com/research/7t6wst/global_veterinary

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

© 2017 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.